Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G

Avacopan, recently FDA approved for ANCA-associated vasculitis, showed significant benefit for reducing disease chronicity in a randomized trial of 52 patients with C3 glomerulopathy.
Medscape Medical News

source https://www.medscape.com/viewarticle/969740?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost